Pingyu Chen, Pingyu Chen, Xintian Wang, Shengwen Zhu, Hongchao Li, Hongchao Li, . . . Aixia Ma. (2022). Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Frontiers Media S.A..
Chicago Style (17th ed.) CitationPingyu Chen, et al. Economic Evaluation of Sintilimab Plus Chemotherapy Vs. Pembrolizumab Plus Chemotherapy for the Treatment of First-line Advanced or Metastatic Squamous NSCLC. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationPingyu Chen, et al. Economic Evaluation of Sintilimab Plus Chemotherapy Vs. Pembrolizumab Plus Chemotherapy for the Treatment of First-line Advanced or Metastatic Squamous NSCLC. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.